Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 15, Issue 5, Pages 417-427
Publisher
Informa UK Limited
Online
2019-04-06
DOI
10.1080/17425255.2019.1604685
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination
- (2018) Robin Augustine et al. Acta Biomaterialia
- The current understanding of the interactions between nanoparticles and cytochrome P450 enzymes- a literature-based review
- (2018) Pan Yan et al. XENOBIOTICA
- Pharmacogenetic considerations for HIV treatment in different ethnicities: an update
- (2017) M. Neary et al. Expert Opinion on Drug Metabolism & Toxicology
- Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial
- (2017) S Gallien et al. HIV MEDICINE
- Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat
- (2017) Md Amin Hossain et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus
- (2017) Xia Liu et al. PHARMACOTHERAPY
- Role and modulation of drug transporters in HIV-1 therapy
- (2016) Camille Alam et al. ADVANCED DRUG DELIVERY REVIEWS
- Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects
- (2016) Srini Ramanathan et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications
- (2016) Catia Marzolini et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects
- (2016) Li Zhu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Current status and prospects of HIV treatment
- (2016) Tomas Cihlar et al. Current Opinion in Virology
- Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia
- (2015) Sunitha Kodidela et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Class-specific relative genetic contribution for key antiretroviral drugs
- (2015) Marco Siccardi et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The potential of HIV-1 nanotherapeutics: fromin vitrostudies to clinical trials
- (2015) Upal Roy et al. Nanomedicine
- The discovery and development of antiretroviral agents
- (2014) Joep MA Lange et al. ANTIVIRAL THERAPY
- Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers
- (2014) Thomas N Kakuda et al. ANTIVIRAL THERAPY
- Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs
- (2014) Giulia Berno et al. BMC Medical Genetics
- Pharmacokinetic Enhancers in HIV Therapeutics
- (2014) Kajal B. Larson et al. CLINICAL PHARMACOKINETICS
- Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies
- (2014) Benson Edagwa et al. CURRENT MEDICINAL CHEMISTRY
- Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization andin vitro/in vivoappraisal
- (2014) Gurinder Singh et al. DRUG DELIVERY
- Cytochrome P450 pharmacogenetics in African populations: implications for public health
- (2014) Collet Dandara et al. Expert Opinion on Drug Metabolism & Toxicology
- Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir
- (2014) Thomas N. Kakuda et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Safe Treatment of Seizures in the Setting of HIV/AIDS
- (2013) Omar Siddiqi et al. Current Treatment Options in Neurology
- Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection
- (2013) Emma D. Deeks DRUGS
- Efficacy and Safety of Tipranavir Coadministered with Ritonavir in HIV-1-Infected Children and Adolescents
- (2013) Juan C. Salazar et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
- (2013) Ulrich M. Zanger et al. PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetic-Pharmacodynamic Modeling of Unboosted Atazanavir in a Cohort of Stable HIV-Infected Patients
- (2012) Sylvain Goutelle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial
- (2012) C Orkin et al. HIV MEDICINE
- Influence of Drug Transport Proteins on the Pharmacokinetics and Drug Interactions of Hiv Protease Inhibitors
- (2011) Latoya Griffin et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
- (2011) Jean-Michel Molina et al. LANCET INFECTIOUS DISEASES
- Antiretroviral Therapy as HIV Prevention: Status and Prospects
- (2010) Kenneth H. Mayer et al. AMERICAN JOURNAL OF PUBLIC HEALTH
- Holy fire in an HIV-positive man: a case of 21st-century ergotism
- (2010) G. Frohlich et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Antiretroviral drugs
- (2010) Erik De Clercq CURRENT OPINION IN PHARMACOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Etravirine
- (2009) Monika Schöller-Gyüre et al. CLINICAL PHARMACOKINETICS
- Polymorphism of human cytochrome P450 enzymes and its clinical impact
- (2009) Shu-Feng Zhou et al. DRUG METABOLISM REVIEWS
- Darunavir
- (2009) Kate McKeage et al. DRUGS
- Pharmacogenomics ofCYP3A: considerations for HIV treatment
- (2009) Sukhwinder S Lakhman et al. PHARMACOGENOMICS
- Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin
- (2008) Pertti J Neuvonen et al. CLINICAL PHARMACOKINETICS
- Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected Patients
- (2008) C Wyen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tipranavir
- (2008) Jennifer S Orman et al. DRUGS
- Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV
- (2008) Erik De Clercq INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
- (2008) C. Wyen et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Drug Interactions Involving Combination Antiretroviral Therapy and Other Anti‐Infective Agents: Repercussions for Resource‐Limited Countries
- (2008) Kelly E. Dooley et al. JOURNAL OF INFECTIOUS DISEASES
- Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver
- (2008) M. H. Hofmann et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started